Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, et al.
Hepatology (2017) Vol. 68, Iss. 1, pp. 361-371
Open Access | Times Cited: 331

Showing 1-25 of 331 citing articles:

Non-alcoholic fatty liver disease – A global public health perspective
Zobair M. Younossi
Journal of Hepatology (2018) Vol. 70, Iss. 3, pp. 531-544
Open Access | Times Cited: 1809
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Zobair M. Younossi, Frank Tacke, Marco Arrese, et al.
Hepatology (2018) Vol. 69, Iss. 6, pp. 2672-2682
Open Access | Times Cited: 1609
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan, Hans‐Ulrich Häring, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 4, pp. 313-324
Closed Access | Times Cited: 737
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Amedeo Lonardo, Fabio Nascimbeni, Stefano Ballestri, et al.
Hepatology (2019) Vol. 70, Iss. 4, pp. 1457-1469
Open Access | Times Cited: 737
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Zobair M. Younossi, Maria Stepanova, Janus P. Ong, et al.
Clinical Gastroenterology and Hepatology (2018) Vol. 17, Iss. 4, pp. 748-755.e3
Open Access | Times Cited: 713
Epidemiology of chronic liver diseases in the USA in the past three decades
Zobair M. Younossi, Maria Stepanova, Youssef Younossi, et al.
Gut (2019) Vol. 69, Iss. 3, pp. 564-568
Closed Access | Times Cited: 455
Bile Acids Activated Receptors Regulate Innate Immunity
Stefano Fiorucci, Michele Biagioli, Angela Zampella, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 423
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review
Rohit Loomba, Joseph K. Lim, Heather Patton, et al.
Gastroenterology (2020) Vol. 158, Iss. 6, pp. 1822-1830
Open Access | Times Cited: 296
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Scott L. Friedman, Massimo Pinzani
Hepatology (2021) Vol. 75, Iss. 2, pp. 473-488
Open Access | Times Cited: 290
Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats
Zehua Zhao, Feng‐Zhi Xin, Yaqian Xue, et al.
Experimental & Molecular Medicine (2019) Vol. 51, Iss. 9, pp. 1-14
Open Access | Times Cited: 251
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong‐Ju Yoo, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 3, pp. 363-401
Open Access | Times Cited: 225
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, et al.
Journal of Gastroenterology (2021) Vol. 56, Iss. 11, pp. 951-963
Open Access | Times Cited: 206
Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease
Carolina M. Perdomo, Gema Frühbeck, Javier Escalada
Nutrients (2019) Vol. 11, Iss. 3, pp. 677-677
Open Access | Times Cited: 189
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Cheng Peng, Alastair G. Stewart, Owen L. Woodman, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 189
Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
James M. Paik, Linda Henry, Leyla de Avila, et al.
Hepatology Communications (2019) Vol. 3, Iss. 11, pp. 1459-1471
Open Access | Times Cited: 187
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
Daniel Lindén, Andrea Ahnmark, Piero Pingitore, et al.
Molecular Metabolism (2019) Vol. 22, pp. 49-61
Open Access | Times Cited: 180
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
Jingjing Cai, Xiao‐Jing Zhang, Hongliang Li
Hepatology (2019) Vol. 70, Iss. 3, pp. 1026-1037
Closed Access | Times Cited: 176
Impact of different ectopic fat depots on cardiovascular and metabolic diseases
Daniele Ferrara, Fabrizio Montecucco, Franco Dallegri, et al.
Journal of Cellular Physiology (2019) Vol. 234, Iss. 12, pp. 21630-21641
Closed Access | Times Cited: 160
Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression
Suzanne R. Sharpton, Bharat Maraj, Emily Harding‐Theobald, et al.
American Journal of Clinical Nutrition (2019) Vol. 110, Iss. 1, pp. 139-149
Open Access | Times Cited: 159
Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis
Xiaoli Sun, Jason S. Seidman, Peng Zhao, et al.
Cell Metabolism (2019) Vol. 31, Iss. 1, pp. 189-206.e8
Open Access | Times Cited: 155
Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf2 axis and PI3K/AKT/mTOR pathway in macrophages
Beibei Liu, Xiaoling Deng, Qianqian Jiang, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 125, pp. 109895-109895
Open Access | Times Cited: 146
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, et al.
Hepatology Research (2021) Vol. 51, Iss. 10, pp. 1013-1025
Open Access | Times Cited: 116
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
Diana Barb, Enrico Repetto, Michael Edward Stokes, et al.
Obesity (2021) Vol. 29, Iss. 11, pp. 1950-1960
Open Access | Times Cited: 113
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
Arun J. Sanyal, Vlad Ratziu, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1110-1120
Open Access | Times Cited: 62
Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease
Suzanne R. Sharpton, Bernd Schnabl, Rob Knight, et al.
Cell Metabolism (2020) Vol. 33, Iss. 1, pp. 21-32
Open Access | Times Cited: 132
Page 1 - Next Page

Scroll to top